Loading…
Monday, June 25 • 11:00am - 12:15pm
#120: FDA Innovation in Pharmaceutical Quality Assessment and Inspection

Sign up or log in to save this to your schedule and see who's attending!

Component Type: Session
Level: Basic
CE: ACPE 1.25 Knowledge UAN: 0286-0000-18-532-L04-P; CME 1.25; IACET 1.25; RN 1.25

FDA’s Office of Regulatory (ORA) and Office of Pharmaceutical Quality (OPQ) within CDER work closely together to provide “one quality for voice” for products including new drugs, biotechnology products, generic drugs, and over-the-counter drugs. Many changes and innovation have occurred since the 2015 stand up of OPQ and the 2017 program alignment within ORA. This session will discuss some of the innovative approaches being used within OPQ and ORA to provide more focused and patient relevant quality assessments, promote review efficiency and innovation for generic drugs and to integrate quality assessment and inspection.`

Learning Objectives

Identify the ongoing FDA initiatives to modernize and integrate the quality assessment and inspection processes for drugs.

Chair

Christine M. V. Moore, PhD

Speaker

Modernization of Quality Assessment of Generic Drugs
Susan M. Rosencrance, PhD

Patient-Focused Quality Within OPQ: Clinically Relevant Specifications and Quality Overall Summary
Ashley Boam, MS

Progress in Integration of Inspection and Quality Assessment
Alonza Cruse



Speakers
avatar for Ashley Boam

Ashley Boam

Director, Office of Policy for Pharmaceutical Quality, OPQ, CDER, FDA
Ashley serves as Director of the Office of Policy for Pharmaceutical Quality in the Center for Drug Evaluation and Research at FDA. OPPQ is responsible for developing and clearly communicating science- and risk-based policies & standards related to drug product quality, including... Read More →
avatar for Alonza Cruse

Alonza Cruse

Director, Office of Pharmaceutical Quality Operations, ORA, OGROP, FDA
Director, Office of Pharmaceutical Quality Operations within FDA’s Office of Regulatory Affairs (ORA), responsible for all pharmaceutical quality inspections & investigations, both foreign & domestic, working in conjunction with FDA Centers: CDER and CVM. Alonza is also leading... Read More →
avatar for Christine Moore

Christine Moore

Global Head and Executive Director, GRACS CMC - Policy, Merck Research Laboratories
Christine Moore is Global Head and Executive Director, CMC Policy at Merck. Christine joined Merck after more than a decade in various positions in the US FDA. Prior to working at FDA, Christine spent 10 years in small and large molecule process development. Throughout her career... Read More →
avatar for Susan Rosencrance

Susan Rosencrance

Director, Office of Lifecycle Drug Products, OPQ, CDER, FDA
Dr. Susan Rosencrance currently serves as the Director for the Office of Lifecycle Drug Products in the Office of Pharmaceutical Quality (OPQ). In this capacity, she directs procedures and processes for evaluating and assessing drug product quality of both brand name and generic drug... Read More →


Monday June 25, 2018 11:00am - 12:15pm
Room 206AB Boston Convention and Exhibition Center 415 Summer Street, Boston, MA 02210 USA